Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
18,515
archived clinical trials in
Lymphoma

A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study
Treatment With SGN-35 in Patients With CD30-positive Hematologic Malignancies Who Have Previously Participated in an SGN-35 Study
Status: Enrolling
Updated:  11/17/2015
Charles A. Sammons Cancer Center
mi
from
Dallas, TX
A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study
Treatment With SGN-35 in Patients With CD30-positive Hematologic Malignancies Who Have Previously Participated in an SGN-35 Study
Status: Enrolling
Updated: 11/17/2015
Charles A. Sammons Cancer Center
mi
from
Dallas, TX
Click here to add this to my saved trials
A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study
Treatment With SGN-35 in Patients With CD30-positive Hematologic Malignancies Who Have Previously Participated in an SGN-35 Study
Status: Enrolling
Updated:  11/17/2015
Hopital Saint-Louis/Service d'Hematologie
mi
from
Paris,
A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study
Treatment With SGN-35 in Patients With CD30-positive Hematologic Malignancies Who Have Previously Participated in an SGN-35 Study
Status: Enrolling
Updated: 11/17/2015
Hopital Saint-Louis/Service d'Hematologie
mi
from
Paris,
Click here to add this to my saved trials
Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies
Vorinostat (SAHA) Combined With High-Dose Gemcitabine, Busulfan, and Melphalan With Autologous Hematopoietic Cell Support for Patients With Relapsed or Refractory Lymphoid Malignancies
Status: Enrolling
Updated:  11/17/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies
Vorinostat (SAHA) Combined With High-Dose Gemcitabine, Busulfan, and Melphalan With Autologous Hematopoietic Cell Support for Patients With Relapsed or Refractory Lymphoid Malignancies
Status: Enrolling
Updated: 11/17/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Food Effect Study of Alisertib (MLN8237) in Patients With Advanced Solid Tumors or Lymphomas
An Open-Label, Phase 1, Two-Way, Cross-Over Study of the Effect of the Food on the Pharmacokinetics of MLN8237 (Alisertib) in Patients With Advanced Solid Tumors or Lymphomas
Status: Enrolling
Updated:  11/17/2015
Clinical Research Facility
mi
from
Bronx, NY
Food Effect Study of Alisertib (MLN8237) in Patients With Advanced Solid Tumors or Lymphomas
An Open-Label, Phase 1, Two-Way, Cross-Over Study of the Effect of the Food on the Pharmacokinetics of MLN8237 (Alisertib) in Patients With Advanced Solid Tumors or Lymphomas
Status: Enrolling
Updated: 11/17/2015
Clinical Research Facility
mi
from
Bronx, NY
Click here to add this to my saved trials
Food Effect Study of Alisertib (MLN8237) in Patients With Advanced Solid Tumors or Lymphomas
An Open-Label, Phase 1, Two-Way, Cross-Over Study of the Effect of the Food on the Pharmacokinetics of MLN8237 (Alisertib) in Patients With Advanced Solid Tumors or Lymphomas
Status: Enrolling
Updated:  11/17/2015
Clinical Research Facility
mi
from
Nashville, TN
Food Effect Study of Alisertib (MLN8237) in Patients With Advanced Solid Tumors or Lymphomas
An Open-Label, Phase 1, Two-Way, Cross-Over Study of the Effect of the Food on the Pharmacokinetics of MLN8237 (Alisertib) in Patients With Advanced Solid Tumors or Lymphomas
Status: Enrolling
Updated: 11/17/2015
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
Food Effect Study of Alisertib (MLN8237) in Patients With Advanced Solid Tumors or Lymphomas
An Open-Label, Phase 1, Two-Way, Cross-Over Study of the Effect of the Food on the Pharmacokinetics of MLN8237 (Alisertib) in Patients With Advanced Solid Tumors or Lymphomas
Status: Enrolling
Updated:  11/17/2015
Clinical Research Facility
mi
from
San Antonio, TX
Food Effect Study of Alisertib (MLN8237) in Patients With Advanced Solid Tumors or Lymphomas
An Open-Label, Phase 1, Two-Way, Cross-Over Study of the Effect of the Food on the Pharmacokinetics of MLN8237 (Alisertib) in Patients With Advanced Solid Tumors or Lymphomas
Status: Enrolling
Updated: 11/17/2015
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Zevalin (Ibritumomab Tiuxetan) for Early Stage Indolent Lymphomas
Phase II Study of Zevalin for the Treatment of Early-Stage Indolent Lymphomas
Status: Enrolling
Updated:  11/17/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Zevalin (Ibritumomab Tiuxetan) for Early Stage Indolent Lymphomas
Phase II Study of Zevalin for the Treatment of Early-Stage Indolent Lymphomas
Status: Enrolling
Updated: 11/17/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
GM-CSF and Rituximab After Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin Lymphoma
A Phase II Study of GM-CSF (Sargramostim) and Rituximab Following Autologous Transplantation For Relapsed Follicular Lymphoma
Status: Enrolling
Updated:  11/18/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
GM-CSF and Rituximab After Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin Lymphoma
A Phase II Study of GM-CSF (Sargramostim) and Rituximab Following Autologous Transplantation For Relapsed Follicular Lymphoma
Status: Enrolling
Updated: 11/18/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
A Phase 2, Multicenter Study in Pediatric Subjects With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma
A Phase 2, Multicenter, Single-arm Study of Moxetumomab Pasudotox in Pediatric Subjects With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma of B-cell Origin
Status: Enrolling
Updated:  11/18/2015
Clinical Research Facility
mi
from
Phoenix, AZ
A Phase 2, Multicenter Study in Pediatric Subjects With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma
A Phase 2, Multicenter, Single-arm Study of Moxetumomab Pasudotox in Pediatric Subjects With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma of B-cell Origin
Status: Enrolling
Updated: 11/18/2015
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Phase 2, Multicenter Study in Pediatric Subjects With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma
A Phase 2, Multicenter, Single-arm Study of Moxetumomab Pasudotox in Pediatric Subjects With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma of B-cell Origin
Status: Enrolling
Updated:  11/18/2015
Clinical Research Facility
mi
from
Los Angeles, CA
A Phase 2, Multicenter Study in Pediatric Subjects With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma
A Phase 2, Multicenter, Single-arm Study of Moxetumomab Pasudotox in Pediatric Subjects With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma of B-cell Origin
Status: Enrolling
Updated: 11/18/2015
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Phase 2, Multicenter Study in Pediatric Subjects With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma
A Phase 2, Multicenter, Single-arm Study of Moxetumomab Pasudotox in Pediatric Subjects With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma of B-cell Origin
Status: Enrolling
Updated:  11/18/2015
Clinical Research Facility
mi
from
Chicago, IL
A Phase 2, Multicenter Study in Pediatric Subjects With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma
A Phase 2, Multicenter, Single-arm Study of Moxetumomab Pasudotox in Pediatric Subjects With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma of B-cell Origin
Status: Enrolling
Updated: 11/18/2015
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
A Phase 2, Multicenter Study in Pediatric Subjects With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma
A Phase 2, Multicenter, Single-arm Study of Moxetumomab Pasudotox in Pediatric Subjects With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma of B-cell Origin
Status: Enrolling
Updated:  11/18/2015
Clinical Research Facility
mi
from
Bethesda, MD
A Phase 2, Multicenter Study in Pediatric Subjects With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma
A Phase 2, Multicenter, Single-arm Study of Moxetumomab Pasudotox in Pediatric Subjects With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma of B-cell Origin
Status: Enrolling
Updated: 11/18/2015
Clinical Research Facility
mi
from
Bethesda, MD
Click here to add this to my saved trials
A Phase 2, Multicenter Study in Pediatric Subjects With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma
A Phase 2, Multicenter, Single-arm Study of Moxetumomab Pasudotox in Pediatric Subjects With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma of B-cell Origin
Status: Enrolling
Updated:  11/18/2015
Clinical Research Facility
mi
from
Kansas City, MO
A Phase 2, Multicenter Study in Pediatric Subjects With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma
A Phase 2, Multicenter, Single-arm Study of Moxetumomab Pasudotox in Pediatric Subjects With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma of B-cell Origin
Status: Enrolling
Updated: 11/18/2015
Clinical Research Facility
mi
from
Kansas City, MO
Click here to add this to my saved trials
A Phase 2, Multicenter Study in Pediatric Subjects With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma
A Phase 2, Multicenter, Single-arm Study of Moxetumomab Pasudotox in Pediatric Subjects With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma of B-cell Origin
Status: Enrolling
Updated:  11/18/2015
Clinical Research Facility
mi
from
New York, NY
A Phase 2, Multicenter Study in Pediatric Subjects With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma
A Phase 2, Multicenter, Single-arm Study of Moxetumomab Pasudotox in Pediatric Subjects With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma of B-cell Origin
Status: Enrolling
Updated: 11/18/2015
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
A Phase 2, Multicenter Study in Pediatric Subjects With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma
A Phase 2, Multicenter, Single-arm Study of Moxetumomab Pasudotox in Pediatric Subjects With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma of B-cell Origin
Status: Enrolling
Updated:  11/18/2015
Clinical Research Facility
mi
from
Durham, NC
A Phase 2, Multicenter Study in Pediatric Subjects With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma
A Phase 2, Multicenter, Single-arm Study of Moxetumomab Pasudotox in Pediatric Subjects With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma of B-cell Origin
Status: Enrolling
Updated: 11/18/2015
Clinical Research Facility
mi
from
Durham, NC
Click here to add this to my saved trials
A Phase 2, Multicenter Study in Pediatric Subjects With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma
A Phase 2, Multicenter, Single-arm Study of Moxetumomab Pasudotox in Pediatric Subjects With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma of B-cell Origin
Status: Enrolling
Updated:  11/18/2015
Clinical Research Facility
mi
from
Columbus, OH
A Phase 2, Multicenter Study in Pediatric Subjects With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma
A Phase 2, Multicenter, Single-arm Study of Moxetumomab Pasudotox in Pediatric Subjects With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma of B-cell Origin
Status: Enrolling
Updated: 11/18/2015
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
A Phase 2, Multicenter Study in Pediatric Subjects With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma
A Phase 2, Multicenter, Single-arm Study of Moxetumomab Pasudotox in Pediatric Subjects With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma of B-cell Origin
Status: Enrolling
Updated:  11/18/2015
Clinical Research Facility
mi
from
Philadelphia, PA
A Phase 2, Multicenter Study in Pediatric Subjects With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma
A Phase 2, Multicenter, Single-arm Study of Moxetumomab Pasudotox in Pediatric Subjects With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma of B-cell Origin
Status: Enrolling
Updated: 11/18/2015
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Phase 2, Multicenter Study in Pediatric Subjects With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma
A Phase 2, Multicenter, Single-arm Study of Moxetumomab Pasudotox in Pediatric Subjects With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma of B-cell Origin
Status: Enrolling
Updated:  11/18/2015
Clinical Research Facility
mi
from
Seattle, WA
A Phase 2, Multicenter Study in Pediatric Subjects With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma
A Phase 2, Multicenter, Single-arm Study of Moxetumomab Pasudotox in Pediatric Subjects With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma of B-cell Origin
Status: Enrolling
Updated: 11/18/2015
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
A Phase 2, Multicenter Study in Pediatric Subjects With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma
A Phase 2, Multicenter, Single-arm Study of Moxetumomab Pasudotox in Pediatric Subjects With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma of B-cell Origin
Status: Enrolling
Updated:  11/18/2015
mi
from
Parkville,
A Phase 2, Multicenter Study in Pediatric Subjects With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma
A Phase 2, Multicenter, Single-arm Study of Moxetumomab Pasudotox in Pediatric Subjects With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma of B-cell Origin
Status: Enrolling
Updated: 11/18/2015
mi
from
Parkville,
Click here to add this to my saved trials
A Study Of Panobinostat In Children With Refractory Hematologic Malignancies
A Phase I Dose Finding Study Of Panobinostat In Children With Refractory Hematologic Malignancies
Status: Enrolling
Updated:  11/20/2015
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
A Study Of Panobinostat In Children With Refractory Hematologic Malignancies
A Phase I Dose Finding Study Of Panobinostat In Children With Refractory Hematologic Malignancies
Status: Enrolling
Updated: 11/20/2015
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study Of Panobinostat In Children With Refractory Hematologic Malignancies
A Phase I Dose Finding Study Of Panobinostat In Children With Refractory Hematologic Malignancies
Status: Enrolling
Updated:  11/20/2015
UCSF School of Medicine
mi
from
San Francisco, CA
A Study Of Panobinostat In Children With Refractory Hematologic Malignancies
A Phase I Dose Finding Study Of Panobinostat In Children With Refractory Hematologic Malignancies
Status: Enrolling
Updated: 11/20/2015
UCSF School of Medicine
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Study Of Panobinostat In Children With Refractory Hematologic Malignancies
A Phase I Dose Finding Study Of Panobinostat In Children With Refractory Hematologic Malignancies
Status: Enrolling
Updated:  11/20/2015
Childrens National Medical Center
mi
from
Washington,
A Study Of Panobinostat In Children With Refractory Hematologic Malignancies
A Phase I Dose Finding Study Of Panobinostat In Children With Refractory Hematologic Malignancies
Status: Enrolling
Updated: 11/20/2015
Childrens National Medical Center
mi
from
Washington,
Click here to add this to my saved trials
A Study Of Panobinostat In Children With Refractory Hematologic Malignancies
A Phase I Dose Finding Study Of Panobinostat In Children With Refractory Hematologic Malignancies
Status: Enrolling
Updated:  11/20/2015
Children's Healthcare of Atlanta/Emory University
mi
from
Atlanta, GA
A Study Of Panobinostat In Children With Refractory Hematologic Malignancies
A Phase I Dose Finding Study Of Panobinostat In Children With Refractory Hematologic Malignancies
Status: Enrolling
Updated: 11/20/2015
Children's Healthcare of Atlanta/Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study Of Panobinostat In Children With Refractory Hematologic Malignancies
A Phase I Dose Finding Study Of Panobinostat In Children With Refractory Hematologic Malignancies
Status: Enrolling
Updated:  11/20/2015
Lurie Children's Hospital
mi
from
Chicago, IL
A Study Of Panobinostat In Children With Refractory Hematologic Malignancies
A Phase I Dose Finding Study Of Panobinostat In Children With Refractory Hematologic Malignancies
Status: Enrolling
Updated: 11/20/2015
Lurie Children's Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study Of Panobinostat In Children With Refractory Hematologic Malignancies
A Phase I Dose Finding Study Of Panobinostat In Children With Refractory Hematologic Malignancies
Status: Enrolling
Updated:  11/20/2015
Dana Farber
mi
from
Boston, MA
A Study Of Panobinostat In Children With Refractory Hematologic Malignancies
A Phase I Dose Finding Study Of Panobinostat In Children With Refractory Hematologic Malignancies
Status: Enrolling
Updated: 11/20/2015
Dana Farber
mi
from
Boston, MA
Click here to add this to my saved trials
A Study Of Panobinostat In Children With Refractory Hematologic Malignancies
A Phase I Dose Finding Study Of Panobinostat In Children With Refractory Hematologic Malignancies
Status: Enrolling
Updated:  11/20/2015
C.S Mott Children's Hospital
mi
from
Ann Arbor, MI
A Study Of Panobinostat In Children With Refractory Hematologic Malignancies
A Phase I Dose Finding Study Of Panobinostat In Children With Refractory Hematologic Malignancies
Status: Enrolling
Updated: 11/20/2015
C.S Mott Children's Hospital
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Study Of Panobinostat In Children With Refractory Hematologic Malignancies
A Phase I Dose Finding Study Of Panobinostat In Children With Refractory Hematologic Malignancies
Status: Enrolling
Updated:  11/20/2015
Childrens Hospital & Clinics of Minnesota
mi
from
Minneapolis, MN
A Study Of Panobinostat In Children With Refractory Hematologic Malignancies
A Phase I Dose Finding Study Of Panobinostat In Children With Refractory Hematologic Malignancies
Status: Enrolling
Updated: 11/20/2015
Childrens Hospital & Clinics of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
A Study Of Panobinostat In Children With Refractory Hematologic Malignancies
A Phase I Dose Finding Study Of Panobinostat In Children With Refractory Hematologic Malignancies
Status: Enrolling
Updated:  11/20/2015
Children's Hospital New York-Presbyterian
mi
from
New York, NY
A Study Of Panobinostat In Children With Refractory Hematologic Malignancies
A Phase I Dose Finding Study Of Panobinostat In Children With Refractory Hematologic Malignancies
Status: Enrolling
Updated: 11/20/2015
Children's Hospital New York-Presbyterian
mi
from
New York, NY
Click here to add this to my saved trials
A Study Of Panobinostat In Children With Refractory Hematologic Malignancies
A Phase I Dose Finding Study Of Panobinostat In Children With Refractory Hematologic Malignancies
Status: Enrolling
Updated:  11/20/2015
Levine Children's Hospital at Carolinas Medical Center
mi
from
Charlotte, NC
A Study Of Panobinostat In Children With Refractory Hematologic Malignancies
A Phase I Dose Finding Study Of Panobinostat In Children With Refractory Hematologic Malignancies
Status: Enrolling
Updated: 11/20/2015
Levine Children's Hospital at Carolinas Medical Center
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Study Of Panobinostat In Children With Refractory Hematologic Malignancies
A Phase I Dose Finding Study Of Panobinostat In Children With Refractory Hematologic Malignancies
Status: Enrolling
Updated:  11/20/2015
Rainbow Babies
mi
from
Cleveland, OH
A Study Of Panobinostat In Children With Refractory Hematologic Malignancies
A Phase I Dose Finding Study Of Panobinostat In Children With Refractory Hematologic Malignancies
Status: Enrolling
Updated: 11/20/2015
Rainbow Babies
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Study Of Panobinostat In Children With Refractory Hematologic Malignancies
A Phase I Dose Finding Study Of Panobinostat In Children With Refractory Hematologic Malignancies
Status: Enrolling
Updated:  11/20/2015
Nationwide Children's Hospital
mi
from
Columbus, OH
A Study Of Panobinostat In Children With Refractory Hematologic Malignancies
A Phase I Dose Finding Study Of Panobinostat In Children With Refractory Hematologic Malignancies
Status: Enrolling
Updated: 11/20/2015
Nationwide Children's Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
A Study Of Panobinostat In Children With Refractory Hematologic Malignancies
A Phase I Dose Finding Study Of Panobinostat In Children With Refractory Hematologic Malignancies
Status: Enrolling
Updated:  11/20/2015
Oregon Health and Science University
mi
from
Portland, OR
A Study Of Panobinostat In Children With Refractory Hematologic Malignancies
A Phase I Dose Finding Study Of Panobinostat In Children With Refractory Hematologic Malignancies
Status: Enrolling
Updated: 11/20/2015
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
A Study Of Panobinostat In Children With Refractory Hematologic Malignancies
A Phase I Dose Finding Study Of Panobinostat In Children With Refractory Hematologic Malignancies
Status: Enrolling
Updated:  11/20/2015
St. Jude
mi
from
Memphis, TN
A Study Of Panobinostat In Children With Refractory Hematologic Malignancies
A Phase I Dose Finding Study Of Panobinostat In Children With Refractory Hematologic Malignancies
Status: Enrolling
Updated: 11/20/2015
St. Jude
mi
from
Memphis, TN
Click here to add this to my saved trials
A Study Of Panobinostat In Children With Refractory Hematologic Malignancies
A Phase I Dose Finding Study Of Panobinostat In Children With Refractory Hematologic Malignancies
Status: Enrolling
Updated:  11/20/2015
Vanderbilt Children's Hospital
mi
from
Nashville, TN
A Study Of Panobinostat In Children With Refractory Hematologic Malignancies
A Phase I Dose Finding Study Of Panobinostat In Children With Refractory Hematologic Malignancies
Status: Enrolling
Updated: 11/20/2015
Vanderbilt Children's Hospital
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study Of Panobinostat In Children With Refractory Hematologic Malignancies
A Phase I Dose Finding Study Of Panobinostat In Children With Refractory Hematologic Malignancies
Status: Enrolling
Updated:  11/20/2015
Primary Children's
mi
from
Salt Lake City, UT
A Study Of Panobinostat In Children With Refractory Hematologic Malignancies
A Phase I Dose Finding Study Of Panobinostat In Children With Refractory Hematologic Malignancies
Status: Enrolling
Updated: 11/20/2015
Primary Children's
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Study Of Panobinostat In Children With Refractory Hematologic Malignancies
A Phase I Dose Finding Study Of Panobinostat In Children With Refractory Hematologic Malignancies
Status: Enrolling
Updated:  11/20/2015
Seattle Children's Hospital
mi
from
Seattle, WA
A Study Of Panobinostat In Children With Refractory Hematologic Malignancies
A Phase I Dose Finding Study Of Panobinostat In Children With Refractory Hematologic Malignancies
Status: Enrolling
Updated: 11/20/2015
Seattle Children's Hospital
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study Of Panobinostat In Children With Refractory Hematologic Malignancies
A Phase I Dose Finding Study Of Panobinostat In Children With Refractory Hematologic Malignancies
Status: Enrolling
Updated:  11/20/2015
Medical College of Wisconsin
mi
from
Milwaukee, WI
A Study Of Panobinostat In Children With Refractory Hematologic Malignancies
A Phase I Dose Finding Study Of Panobinostat In Children With Refractory Hematologic Malignancies
Status: Enrolling
Updated: 11/20/2015
Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
A Study Of Panobinostat In Children With Refractory Hematologic Malignancies
A Phase I Dose Finding Study Of Panobinostat In Children With Refractory Hematologic Malignancies
Status: Enrolling
Updated:  11/20/2015
University of Miami Cancer Center
mi
from
Miami, FL
A Study Of Panobinostat In Children With Refractory Hematologic Malignancies
A Phase I Dose Finding Study Of Panobinostat In Children With Refractory Hematologic Malignancies
Status: Enrolling
Updated: 11/20/2015
University of Miami Cancer Center
mi
from
Miami, FL
Click here to add this to my saved trials
A Study Of Panobinostat In Children With Refractory Hematologic Malignancies
A Phase I Dose Finding Study Of Panobinostat In Children With Refractory Hematologic Malignancies
Status: Enrolling
Updated:  11/20/2015
New York Univ. Medical Center
mi
from
New York, NY
A Study Of Panobinostat In Children With Refractory Hematologic Malignancies
A Phase I Dose Finding Study Of Panobinostat In Children With Refractory Hematologic Malignancies
Status: Enrolling
Updated: 11/20/2015
New York Univ. Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
A Phase I Trial of NECTAR (Nelarabine, Etoposide and Cyclophosphamide in T-ALL Relapse): A Joint Study of TACL and POETIC
Status: Enrolling
Updated:  11/20/2015
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
A Phase I Trial of NECTAR (Nelarabine, Etoposide and Cyclophosphamide in T-ALL Relapse): A Joint Study of TACL and POETIC
Status: Enrolling
Updated: 11/20/2015
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
A Phase I Trial of NECTAR (Nelarabine, Etoposide and Cyclophosphamide in T-ALL Relapse): A Joint Study of TACL and POETIC
Status: Enrolling
Updated:  11/20/2015
Children's Hospital of Orange County
mi
from
Orange, CA
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
A Phase I Trial of NECTAR (Nelarabine, Etoposide and Cyclophosphamide in T-ALL Relapse): A Joint Study of TACL and POETIC
Status: Enrolling
Updated: 11/20/2015
Children's Hospital of Orange County
mi
from
Orange, CA
Click here to add this to my saved trials
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
A Phase I Trial of NECTAR (Nelarabine, Etoposide and Cyclophosphamide in T-ALL Relapse): A Joint Study of TACL and POETIC
Status: Enrolling
Updated:  11/20/2015
UCSF School of Medicine
mi
from
San Francisco, CA
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
A Phase I Trial of NECTAR (Nelarabine, Etoposide and Cyclophosphamide in T-ALL Relapse): A Joint Study of TACL and POETIC
Status: Enrolling
Updated: 11/20/2015
UCSF School of Medicine
mi
from
San Francisco, CA
Click here to add this to my saved trials
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
A Phase I Trial of NECTAR (Nelarabine, Etoposide and Cyclophosphamide in T-ALL Relapse): A Joint Study of TACL and POETIC
Status: Enrolling
Updated:  11/20/2015
The Children's Hospital, University of Colorado
mi
from
Aurora, CO
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
A Phase I Trial of NECTAR (Nelarabine, Etoposide and Cyclophosphamide in T-ALL Relapse): A Joint Study of TACL and POETIC
Status: Enrolling
Updated: 11/20/2015
The Children's Hospital, University of Colorado
mi
from
Aurora, CO
Click here to add this to my saved trials
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
A Phase I Trial of NECTAR (Nelarabine, Etoposide and Cyclophosphamide in T-ALL Relapse): A Joint Study of TACL and POETIC
Status: Enrolling
Updated:  11/20/2015
Childrens National Medical Center
mi
from
Washington,
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
A Phase I Trial of NECTAR (Nelarabine, Etoposide and Cyclophosphamide in T-ALL Relapse): A Joint Study of TACL and POETIC
Status: Enrolling
Updated: 11/20/2015
Childrens National Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
A Phase I Trial of NECTAR (Nelarabine, Etoposide and Cyclophosphamide in T-ALL Relapse): A Joint Study of TACL and POETIC
Status: Enrolling
Updated:  11/20/2015
Children's Healthcare of Atlanta/Emory University
mi
from
Atlanta, GA
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
A Phase I Trial of NECTAR (Nelarabine, Etoposide and Cyclophosphamide in T-ALL Relapse): A Joint Study of TACL and POETIC
Status: Enrolling
Updated: 11/20/2015
Children's Healthcare of Atlanta/Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
A Phase I Trial of NECTAR (Nelarabine, Etoposide and Cyclophosphamide in T-ALL Relapse): A Joint Study of TACL and POETIC
Status: Enrolling
Updated:  11/20/2015
Lurie Children's Hospital
mi
from
Chicago, IL
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
A Phase I Trial of NECTAR (Nelarabine, Etoposide and Cyclophosphamide in T-ALL Relapse): A Joint Study of TACL and POETIC
Status: Enrolling
Updated: 11/20/2015
Lurie Children's Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
A Phase I Trial of NECTAR (Nelarabine, Etoposide and Cyclophosphamide in T-ALL Relapse): A Joint Study of TACL and POETIC
Status: Enrolling
Updated:  11/20/2015
Johns Hopkins University
mi
from
Baltimore, MD
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
A Phase I Trial of NECTAR (Nelarabine, Etoposide and Cyclophosphamide in T-ALL Relapse): A Joint Study of TACL and POETIC
Status: Enrolling
Updated: 11/20/2015
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
A Phase I Trial of NECTAR (Nelarabine, Etoposide and Cyclophosphamide in T-ALL Relapse): A Joint Study of TACL and POETIC
Status: Enrolling
Updated:  11/20/2015
Dana Farber
mi
from
Boston, MA
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
A Phase I Trial of NECTAR (Nelarabine, Etoposide and Cyclophosphamide in T-ALL Relapse): A Joint Study of TACL and POETIC
Status: Enrolling
Updated: 11/20/2015
Dana Farber
mi
from
Boston, MA
Click here to add this to my saved trials
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
A Phase I Trial of NECTAR (Nelarabine, Etoposide and Cyclophosphamide in T-ALL Relapse): A Joint Study of TACL and POETIC
Status: Enrolling
Updated:  11/20/2015
C.S Mott Children's Hospital
mi
from
Ann Arbor, MI
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
A Phase I Trial of NECTAR (Nelarabine, Etoposide and Cyclophosphamide in T-ALL Relapse): A Joint Study of TACL and POETIC
Status: Enrolling
Updated: 11/20/2015
C.S Mott Children's Hospital
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
A Phase I Trial of NECTAR (Nelarabine, Etoposide and Cyclophosphamide in T-ALL Relapse): A Joint Study of TACL and POETIC
Status: Enrolling
Updated:  11/20/2015
Childrens Hospital & Clinics of Minnesota
mi
from
Minneapolis, MN
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
A Phase I Trial of NECTAR (Nelarabine, Etoposide and Cyclophosphamide in T-ALL Relapse): A Joint Study of TACL and POETIC
Status: Enrolling
Updated: 11/20/2015
Childrens Hospital & Clinics of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials